Alvocidib (Flavopiridol)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

Mechanism of action

From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO

Preliminary data

Acute myeloid leukemia

FLAM

back to top

FLAM: FLavopiridol (Alvocidib), Ara-C (Cytarabine), Mitoxantrone

Regimen

Study Evidence Comparator Efficacy
Zeidner et al. 2015 (JHOC-J1101) Randomized Phase II (E) 7+3d, high-dose dauno Superior CR rate

Chemotherapy

One course

References

  1. JHOC-J1101: Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article contains verified protocol link to PMC article PubMed

Chronic lymphocytic leukemia (CLL/SLL)

History of changes in FDA indication

Also known as

  • Code names: HMR 1275, L-868275